{
    "clinical_study": {
        "@rank": "38596", 
        "arm_group": [
            {
                "arm_group_label": "Pelvic Rehabilitation", 
                "arm_group_type": "Active Comparator", 
                "description": "Pelvic Rehabilitation will be conduction on weekly basis for a total of 6 weeks"
            }, 
            {
                "arm_group_label": "Trigger Point Injections", 
                "arm_group_type": "Active Comparator", 
                "description": "Trigger point injections will be administered on weekly basis for a total of 6 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate which treatment option for pelvic floor pain allows\n      for improved sexual function."
        }, 
        "brief_title": "Trigger Point Injections and Pelvic Rehabilitation for the Treatment of Pelvic Floor Myalgia and Sexual Pain", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Dyspareunia", 
        "condition_browse": {
            "mesh_term": "Dyspareunia"
        }, 
        "detailed_description": {
            "textblock": "Pelvic floor pain may be treated with trigger point injections with medications (steroids\n      and local anesthetics) that are FDA approved for injection into muscles. The alternative is\n      a noninvasive treatment option using pelvic rehabilitation which involves vaginal muscle\n      massage. Both treatment options have been used and reported; however, rapidity of\n      improvement and return to normal sexual function have not been assessed. This study assigns\n      patients to either treatment option randomly and the sexual function is assessed based on\n      standardized sexual function questionnaires as well as pain ratings."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  pelvic pain\n\n          -  pelvic floor myalgia\n\n          -  dyspareunia\n\n          -  female\n\n          -  age > 18 years\n\n        Exclusion Criteria:\n\n          -  interstitial cystitis\n\n          -  vaginal lesions / ulcerations\n\n          -  prior trigger point injections in the past 6 months\n\n          -  prior pelvic rehabilitation in the past 6 months\n\n          -  laparoscopically documented endometriosis / pelvic adhesions or adhesive disease\n\n          -  documented pelvic inflammatory disease identified within the past 6 months\n\n          -  documented sexually transmitted disease within the past 6 months"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02022722", 
            "org_study_id": "UC IRB Study #: 2013-0677", 
            "secondary_id": "Patty Brisben Foundation"
        }, 
        "intervention": [
            {
                "arm_group_label": "Trigger Point Injections", 
                "description": "The mixture is injected into the levator muscles, with half the volume on each side of the pelvic musculature.", 
                "intervention_name": "Trigger Point Injections  Triamcinolone Acetonide,  Bupivacaine Hydrochloride", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Triamcinolone Acetonide-Total dose of 40mg, Volume 2 ml", 
                    "Bupivacaine Hydrochloride-Strength 0.5%, Volume 18ml"
                ]
            }, 
            {
                "arm_group_label": "Pelvic Rehabilitation", 
                "description": "Pelvic floor massage will be performed on a weekly basis by a licensed physiotherapist specialized in pelvic floor pelvic therapy", 
                "intervention_name": "Pelvic Rehabilitation", 
                "intervention_type": "Procedure", 
                "other_name": "Pelvic floor massage"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Bupivacaine", 
                "Triamcinolone hexacetonide", 
                "Triamcinolone", 
                "Triamcinolone Acetonide", 
                "Triamcinolone diacetate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Pelvic Floor Myalgia", 
            "Trigger Point Injections", 
            "Pelvic Rehabilitation", 
            "Dyspareunia"
        ], 
        "lastchanged_date": "December 27, 2013", 
        "location": {
            "contact": {
                "email": "zoorobdg@ucmail.uc.edu", 
                "last_name": "Dani Zoorob, MD", 
                "phone": "513-562-9080"
            }, 
            "facility": {
                "address": {
                    "city": "Cincinnati", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "45219"
                }, 
                "name": "Division of Urogynecology, University of Cincinnati Medical Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Assessment Of Pain Subsidence And Sexual Function Amelioration Using Either Pelvic Rehabilitation Or Trigger Point Injections", 
        "overall_contact": {
            "email": "zoorobdg@ucmail.uc.edu", 
            "last_name": "Dani Zoorob, MD", 
            "phone": "5135629080"
        }, 
        "overall_contact_backup": {
            "email": "southmm@ucmai.uc.edu", 
            "last_name": "Mary South, MD", 
            "phone": "5135629080"
        }, 
        "overall_official": {
            "affiliation": "University of Cincinnati", 
            "last_name": "Mary South, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Patients will be asked to rate their current pain prior to initiation of the treatment at the visits, at the start of the study and after the completion of the study, using the 10 point Iowa Pain scale.", 
            "measure": "Change in rating of pain from baseline until the end of the study according to the Iowa Pain Scale", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Week 10"
        }, 
        "reference": {
            "PMID": "8598948", 
            "citation": "Mathias SD, Kuppermann M, Liberman RF, Lipschutz RC, Steege JF. Chronic pelvic pain: prevalence, health-related quality of life, and economic correlates. Obstet Gynecol. 1996 Mar;87(3):321-7."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02022722"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Cincinnati", 
            "investigator_full_name": "Mary South", 
            "investigator_title": "MD, Director of Female Pelvic Medicine & Reconstructive Surgery", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "results_reference": [
            {
                "PMID": "19222415", 
                "citation": "Rao SS, Paulson J, Mata M, Zimmerman B. Clinical trial: effects of botulinum toxin on Levator ani syndrome--a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2009 May 1;29(9):985-91. doi: 10.1111/j.1365-2036.2009.03964.x. Epub 2009 Feb 13."
            }, 
            {
                "PMID": "17195176", 
                "citation": "Langford CF, Udvari Nagy S, Ghoniem GM. Levator ani trigger point injections: An underutilized treatment for chronic pelvic pain. Neurourol Urodyn. 2007;26(1):59-62."
            }, 
            {
                "PMID": "15089868", 
                "citation": "Jarvis SK, Abbott JA, Lenart MB, Steensma A, Vancaillie TG. Pilot study of botulinum toxin type A in the treatment of chronic pelvic pain associated with spasm of the levator ani muscles. Aust N Z J Obstet Gynaecol. 2004 Feb;44(1):46-50."
            }
        ], 
        "secondary_outcome": {
            "description": "Change in sexual function based on the female sexual function index (19 questions, one final score, maximum score of 36) where the patients fill a questionnaire prior to the first treatment session and after the completion of the treatment at week 10.", 
            "measure": "Change in sexual function between visit 1 and visit 10", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Week 10"
        }, 
        "source": "University of Cincinnati", 
        "sponsors": {
            "collaborator": {
                "agency": "Patty Brisben Foundation For Women's Sexual Health", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University of Cincinnati", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}